Drugging the undruggable RAS: Mission Possible?
Open accessThe DOI matches its Crossref record; 231 of the 231 references it cites were found in a registry or an index.
Abstract
Despite more than three decades of intensive effort, no effective pharmacological inhibitors of the RAS oncoproteins have reached the clinic, prompting the widely held perception that RAS proteins are 'undruggable'. However, recent data from the laboratory and the clinic have renewed our hope for the development of RAS-inhibitory molecules. In this Review, we summarize the progress and the promise of five key approaches. Firstly, we focus on the prospects of using direct inhibitors of RAS. Secondly, we address the issue of whether blocking RAS membrane association is a viable approach. Thirdly, we assess the status of targeting RAS downstream effector signalling, which is arguably the most favourable current approach. Fourthly, we address whether the search for synthetic lethal interactors of mutant RAS still holds promise. Finally, RAS-mediated changes in cell metabolism have recently been described and we discuss whether these changes could be exploited for new therapeutic directions. We conclude with perspectives on how additional complexities, which are not yet fully understood, may affect each of these approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“KRAS has historically been considered ‘undruggable’ owing to a lack of pharmacologically targetable pockets within the mutant isoforms.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genetic analysis has shown that 98% of RAS mutations that cause cancer are concentrated in three residues: G12, G13, and Q61.”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of highly selective and potent inhibitors have been developed against kinases in the Ras signaling network particularly those in the MAPK and PI3K/mTOR pathways (9, 12).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For more than 40 years, KRAS mutation has been considered “undruggable” [16, 17].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For many proteins known to be involved in driving diseases, such as KRAS in many cancers, conventional drug development strategies often aimed at developing inhibitors have failed [118, 119].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [119]
Experimental — accuracy not yet measured
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation
Lunt, S. Y., & Vander Heiden, M. G. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154237 · Cited by 3,057
Research works printed but not linked: 1
- Kumar, M. S. et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149, 642–655 (2012). · DOI · Paper page
Cited by
Items 101–200 of 1,007
The evolving landscape of biomarker testing for non-small cell lung cancer in Europe
Kerr, K. M., Bibeau, F., Thunnissen, E., Botling, J., Ryška, A., Wolf, J., Öhrling, K., Burdon, P., Malapelle, U., & Büttner, R. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.02.026 · Cited by 202
XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer
Kim, J., McMillan, E., Kim, H. S., Venkateswaran, N., Makkar, G., Rodriguez-Canales, J., Villalobos, P., Neggers, J. E., Mendiratta, S., Wei, S., et al. (2016) · Nature · doi:10.1038/nature19771 · Cited by 202
KRAS inhibitors: resistance drivers and combinatorial strategies
Isermann, T., Sers, C., Der, C. J., & Papke, B. (2025) · Trends in Cancer · doi:10.1016/j.trecan.2024.11.009 · Cited by 196
Self-citationKRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
Adderley, H., Blackhall, F. H., & Lindsay, C. R. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.049 · Cited by 195
“Historically Ras has been described as an “undruggable” target [8], and despite more”
BackgroundPlatinum coordination compounds with potent anticancer activity
Deo, K. M., Ang, D. L., McGhie, B., Rajamanickam, A., Dhiman, A., Khoury, A., Holland, J., Bjelosevic, A., Pages, B., Gordon, C., et al. (2018) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2017.11.014 · Cited by 191
The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
Kwan, A. K., Piazza, G. A., Keeton, A. B., & Leite, C. A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02225-w · Cited by 180
“Single base missense mutations at these three key residues account for 99% of all RAS mutations [47].”
BackgroundDrugging Ras GTPase: a comprehensive mechanistic and signaling structural view
Lu, S., Jang, H., Gu, S., Zhang, J., & Nussinov, R. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00911a · Cited by 188
Karkou, V., Aithal, S., Zubala, A., & Meekums, B. (2019) · Frontiers in Psychology · doi:10.3389/fpsyg.2019.00936 · Cited by 186
“With children and adolescents, Cox et al. (2014) found it more difficult to establish a clear superiority of psychological interventions over antidepressant medication.”
BackgroundAutophagy and Ferroptosis—What Is the Connection?
Kang, R., & Tang, D. (2017) · Current Pathobiology Reports · doi:10.1007/s40139-017-0139-5 · Cited by 185
KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
Nagasaka, M., Li, Y., Sukari, A., Ou, S.-H. I., Al-Hallak, M. N., & Azmi, A. S. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101974 · Cited by 185
Lee, H. W., Chung, W., Lee, H.-O., Jeong, D. E., Jo, A., Lim, J. E., Hong, J. H., Nam, D.-H., Jeong, B. C., Park, S. H., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-00741-6 · Cited by 183
Pietrantonio, F., Vernieri, C., Siravegna, G., Mennitto, A., Berenato, R., Perrone, F., Gloghini, A., Tamborini, E., Lonardi, S., Morano, F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1863 · Cited by 182
“However, KRAS activating mutations, the most frequent mechanism, have not been successfully targeted so far (23); whether inhibitors of downstream KRAS effectors, e.”
BackgroundEmerging EPO and EPO receptor regulators and signal transducers
Kuhrt, D., & Wojchowski, D. M. (2015) · Blood · doi:10.1182/blood-2014-11-575357 · Cited by 181
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
Zeitouni, D., Pylayeva-Gupta, Y., Der, C., & Bryant, K. (2016) · Cancers · doi:10.3390/cancers8040045 · Cited by 179
“There are four main pharmacologic approaches for inhibition of PI3K signaling: PI3K inhibitors, AKT inhibitors, and mTOR inhibitors, and dual PI3K-mTOR inhibitors [14,91].”
BackgroundInfluentialSelf-citationKaiser, C. E., Van Ert, N. A., Agrawal, P., Chawla, R., Yang, D., & Hurley, L. H. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b02046 · Cited by 179
HMGB1 regulates erastin-induced ferroptosis via RAS-JNK/p38 signaling in HL-60/NRASQ61L cells.
Ye, F., Chai, W., Xie, M., Yang, M., Yan, Y., Cao, L., & Yang, L. (2019) · PubMed · Cited by 202
Ross, S. J., Revenko, A. S., Hanson, L. L., Ellston, R., Staniszewska, A., Whalley, N., Pandey, S. K., Revill, M., Rooney, C., Buckett, L. K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal5253 · Cited by 177
KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy
Ryan, M. B., Coker, O., Sorokin, A., Fella, K., Barnes, H., Wong, E., Kanikarla, P., Gao, F., Zhang, Y., Zhou, L., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110993 · Cited by 177
“Graphical Abstract INTRODUCTION RAS is the most frequently mutated oncogene in cancer and previously considered to be an undruggable target (Cox et al., 2014; Ryan and Corcoran, 2018).”
BackgroundSurvival of pancreatic cancer cells lacking KRAS function
Muzumdar, M. D., Chen, P.-Y., Dorans, K. J., Chung, K. M., Bhutkar, A., Hong, E., Noll, E. M., Sprick, M. R., Trumpp, A., & Jacks, T. (2017) · Nature Communications · doi:10.1038/s41467-017-00942-5 · Cited by 177
Allosteric Modulator Discovery: From Serendipity to Structure-Based Design
Lu, S., He, X., Ni, D., & Zhang, J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01749 · Cited by 169
KRAS G12C inhibition produces a driver-limited state revealing collateral dependencies
Lou, K., Steri, V., Ge, A. Y., Hwang, Y. C., Yogodzinski, C. H., Shkedi, A. R., Choi, A. L. M., Mitchell, D. C., Swaney, D. L., Hann, B., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aaw9450 · Cited by 175
Fluorine-containing drugs approved by the FDA in 2021
He, J., Li, Z., Dhawan, G., Zhang, W., Sorochinsky, A. E., Butler, G., Soloshonok, V. A., & Han, J. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.06.001 · Cited by 172
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
Porru, M., Pompili, L., Caruso, C., Biroccio, A., & Leonetti, C. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0719-1 · Cited by 170
“The knowledge of the biochemical defects in mutant RAS proteins was the starting point in developing the first RAS inhibitor but attempts to discover small molecules able to antagonize RAS-GTP binding failed due to the picomolar affinity of RAS for GTP and the millimolar cellular concentrations of GTP [9, 19].”
BackgroundInfluentialCombinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling
Liu, C., Lu, H., Wang, H., Loo, A., Zhang, X., Yang, G., Kowal, C., Delach, S., Wang, Y., Goldoni, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2718 · Cited by 167
“A large arsenal of inhibitors targeting different nodes of this pathway including RTKs, KRAS, BRAF, CRAF, MEK1/2, and ERK1/2 have been developed to treat RTK- and MAPK-dependent cancers (2).”
BackgroundRAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
Downward, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2180 · Cited by 166
“Because of space constraints, I will not review drug screens for KRAS-mutant cell selective compounds further here, but refer to other recent reviews (5, 34, 35).”
BackgroundIdentification of pyrazolopyridazinones as PDEδ inhibitors
Papke, B., Murarka, S., Vogel, H. A., Martín-Gago, P., Kovacevic, M., Truxius, D. C., Fansa, E. K., Ismail, S., Zimmermann, G., Heinelt, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms11360 · Cited by 160
Kitai, H., Ebi, H., Tomida, S., Floros, K. V., Kotani, H., Adachi, Y., Oizumi, S., Nishimura, M., Faber, A. C., & Yano, S. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1377 · Cited by 162
“In contrast, there are no approved targeted therapies for the treatment of KRAS mutant cancers because direct inhibition of mutant KRAS has proven challenging, despite the development of small-molecule inhibitors that interfere with the localization of KRAS or inhibit the activity of mutant KRAS (3).”
BackgroundThe Mevalonate Pathway, a Metabolic Target in Cancer Therapy
Guerra, B., Recio, C., Aranda-Tavío, H., Guerra-Rodríguez, M., García-Castellano, J. M., & Fernández-Pérez, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.626971 · Cited by 157
Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers
Dillon, M., Lopez, A., Lin, E., Sales, D., Perets, R., & Jain, P. (2021) · Cancers · doi:10.3390/cancers13205059 · Cited by 158
“by geranylgeranyl transferase 1 (GGTase1) if FTase is inhibited [43,45].”
BackgroundNRAS mutant melanoma: Towards better therapies
Randic, T., Kozar, I., Margue, C., Utikal, J. S., & Kreis, S. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102238 · Cited by 189
“Aberrant RAS function in RASmut human tumors is mainly caused by oncogenic missense mutations at codons 12, 13, or 61 [40].”
BackgroundKRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge
Mao, Z., Xiao, H., Shen, P., Yang, Y., Xue, J., Yang, Y., Shang, Y., Zhang, L., Li, X., Zhang, Y., et al. (2022) · Cell Discovery · doi:10.1038/s41421-021-00368-w · Cited by 158
Mechanisms of Resistance to KRASG12C-Targeted Therapy
Akhave, N. S., Biter, A. B., & Hong, D. S. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1616 · Cited by 156
“Unfortunately, targeting mutated KRAS have been unsuccessful despite 40 years of sustained research and development, with generally limited response rates and short durations of response (14,15).”
BackgroundPrecise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer
Xu, J., Liu, Y., Li, Y., Wang, H., Stewart, S., der Jeught, K. V., Agarwal, P., Zhang, Y., Liu, S., Zhao, G., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0381-6 · Cited by 155
“RNA interference (RNAi) with small interfering RNA (siRNA) can be used to target virtually any genes 16–18 .”
The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance
Biancur, D. E., & Kimmelman, A. C. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.04.011 · Cited by 152
Self-citationA Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer
Wei, D., Wang, L., Zuo, X., Maitra, A., & Bresalier, R. S. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2098 · Cited by 192
Weiss, A., Lorthiois, E., Barys, L., Beyer, K. S., Bomio-Confaglia, C., Burks, H., Chen, X., Cui, X., de Kanter, R., Dharmarajan, L., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0158 · Cited by 150
“…nucleotides, an apparent absence of targetable allosteric sites, and the clinical failure of attempts to target other critical aspects of KRAS functioning such as KRAS membrane attachment (6) or inhibition of downstream signaling in the absence of direct selective inhibition of the driver oncogene.”
MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma
Yohe, M. E., Gryder, B. E., Shern, J. F., Song, Y. K., Chou, H.-C., Sindiri, S., Mendoza, A., Patidar, R., Zhang, X., Guha, R., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan4470 · Cited by 145
Drp1 Promotes KRas-Driven Metabolic Changes to Drive Pancreatic Tumor Growth
Nagdas, S., Kashatus, J. A., Nascimento, A., Hussain, S. S., Trainor, R. E., Pollock, S. R., Adair, S. J., Michaels, A. D., Sesaki, H., Stelow, E. B., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.031 · Cited by 146
“Up to 90% of PDAC cases harbor a mutation in the gene encoding KRas (Cox et al., 2014; Ryan et al., 2014), leading to its constitutive activation.”
The Conundrum of Genetic “Drivers” in Benign Conditions
Kato, S., Lippman, S. M., Flaherty, K. T., & Kurzrock, R. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw036 · Cited by 146
“cases), colorectal adenocarcinoma (35%-45%), and lung adenocarcinoma (19%-31%) (19,62,64).”
BackgroundInfluentialKey signaling pathways in thyroid cancer
Zaballos, M. A., & Santisteban, P. (2017) · Journal of Endocrinology · doi:10.1530/joe-17-0266 · Cited by 175
“A common ALK fusion, STRN/ALK , leads to the activation of ALK and MEK-ERK, and increases cell proliferation and transformation in vitro and in vivo (Kelly et al. 2014), supporting the role of ALK rearrangements as early drivers of thyroid carcinogenesis.”
InfluentialMorkel, M., Riemer, P., Bläker, H., & Sers, C. (2015) · Oncotarget · doi:10.18632/oncotarget.4750 · Cited by 144
“KRAS itself, being a small GTPase, has proven to be largely “undruggable” to date, despite recent promising developments [91].”
BackgroundShin, S., Choi, D.-K., Jung, K., Bae, J., Kim, J., Park, S.-W., Song, K.-H., & Kim, Y. (2017) · Nature Communications · doi:10.1038/ncomms15090 · Cited by 149
ABHD17 regulation of plasma membrane palmitoylation and N-Ras-dependent cancer growth
Remsberg, J. R., Suciu, R. M., Zambetti, N. A., Hanigan, T. W., Firestone, A. J., Inguva, A., Long, A., Ngo, N., Lum, K. M., Henry, C. L., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00785-8 · Cited by 141
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer
Tong, X., Patel, A. S., Kim, E., Li, H., Chen, Y., Li, S., Liu, S., Dilly, J., Kapner, K. S., Zhang, N., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.01.012 · Cited by 142
Targeting the Small GTPase Superfamily through Their Regulatory Proteins
Gray, J. L., von Delft, F., & Brennan, P. E. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201900585 · Cited by 142
Zhao, X., Liu, L., Lang, J., Cheng, K., Wang, Y., Li, X., Shi, J., Wang, Y., & Nie, G. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.05.042 · Cited by 136
ADAM 17 selectively activates the IL ‐6 trans‐signaling/ ERK MAPK axis in KRAS ‐addicted lung cancer
Saad, M. I., Alhayyani, S., McLeod, L., Yu, L., Alanazi, M., Deswaerte, V., Tang, K., Jarde, T., Smith, J. A., Prodanovic, Z., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809976 · Cited by 136
“Despite these observations, the development and clinical implementation of specific KRAS inhibitors have proven technically challenging, and there is now a pressing need to identify druggable cooperating partners of oncogenic KRAS (Cox et al, 2014).”
BackgroundIntracellular HMGB1 as a novel tumor suppressor of pancreatic cancer
Kang, R., Xie, Y., Zhang, Q., Hou, W., Jiang, Q., Zhu, S., Liu, J., Zeng, D., Wang, H., Bartlett, D. L., et al. (2017) · Cell Research · doi:10.1038/cr.2017.51 · Cited by 140
Cruz-Migoni, A., Canning, P., Quevedo, C. E., Bataille, C. J. R., Bery, N., Miller, A., Russell, A. J., Phillips, S. E. V., Carr, S. B., & Rabbitts, T. H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811360116 · Cited by 135
“T oncogenic family of RAS genes is of significant interest in the fight against cancer because of the frequency of activating mutations (1).”
BackgroundTargeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future
Uras, I. Z., Moll, H. P., & Casanova, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124325 · Cited by 135
“The precise biological mechanisms driving KRAS membrane association, the enzymology of such modifications, the significance of their stoichiometry and their potential therapeutic value should be fully characterized before entering clinical testing [7,35].”
BackgroundInfluentialUtility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary
Kato, S., Krishnamurthy, N., Banks, K. C., De, P., Williams, K., Williams, C., Leyland-Jones, B., Lippman, S. M., Lanman, R. B., & Kurzrock, R. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0628 · Cited by 134
“Basic characteristics (N=442) Age, median (range), year 65 (20-94) Female, No.”
KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma
Cicenas, J., Tamošaitis, L., Kvederavičiūtė, K., Tarvydas, R., Staniute, G., Kalyan, K. P., Meškinytė-Kaušilienė, E., Stankevičius, V., & Valius, M. (2017) · Medical Oncology · doi:10.1007/s12032-016-0879-9 · Cited by 159
A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
Bery, N., Miller, A., & Rabbitts, T. (2020) · Nature Communications · doi:10.1038/s41467-020-17022-w · Cited by 132
Targeting RAS -mutant Cancers: Is ERK the Key?
Ryan, M. B., Der, C. J., Wang-Gillam, A., & Cox, A. D. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.10.001 · Cited by 131
“The three RAS genes (HRAS, NRAS and KRAS) comprise the most frequently mutated gene family in cancer, with KRAS by far the most commonly mutated of these[2,3] (Figure 2a).”
BackgroundInfluentialSelf-citationDai, C. (2017) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2016.0525 · Cited by 143
Kong, C., Li, Y., Liu, Z., Ye, J., Wang, Z., Zhang, L., Kong, W., Liu, H., Liu, C., Pang, H., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b08246 · Cited by 127
Chakrabarti, G., Moore, Z. R., Luo, X., Ilcheva, M., Ali, A., Padanad, M., Zhou, Y., Xie, Y., Burma, S., Scaglioni, P. P., et al. (2015) · Cancer & Metabolism · doi:10.1186/s40170-015-0137-1 · Cited by 131
“Despite significant effort from the pharmaceutical industry over the past 30 years, KRAS has proven to be a challenging drug target [3].”
BackgroundSelf-citationOncogenic KRAS and BRAF Drive Metabolic Reprogramming in Colorectal Cancer
Hutton, J. E., Wang, X., Zimmerman, L. J., Slebos, R. J. C., Trenary, I. A., Young, J. D., Li, M., & Liebler, D. C. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.058925 · Cited by 131
Nussinov, R., Jang, H., Tsai, C.-J., & Cheng, F. (2019) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1006658 · Cited by 130
The role of wild type RAS isoforms in cancer
Zhou, B., Der, C. J., & Cox, A. D. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.07.012 · Cited by 130
“underlying assumption was that RAS proteins are functionally redundant and thus interchangeable, which turned out to be an oversimplification that resulted in numerous wrong turns in the RAS field [4].”
BackgroundInfluentialSelf-citationATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition
Wang, B., Krall, E. B., Aguirre, A. J., Kim, M., Widlund, H. R., Doshi, M. B., Sicinska, E., Sulahian, R., Goodale, A., Cowley, G. S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.01.031 · Cited by 128
“Although the majority of cancers with mutant RAS depend on oncogenic RAS signaling for proliferation and survival, direct inhibitors of oncogenic RAS proteins have not yet been developed for clinical use (Chien et al., 2006; Cox et al., 2014; Stephen et al., 2014).”
BackgroundKRasG12C inhibitors in clinical trials: a short historical perspective
Goebel, L., Müller, M. P., Goody, R. S., & Rauh, D. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00096e · Cited by 126
MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival
Lee, C.-S., Lee, L. C., Yuan, T. L., Chakka, S., Fellmann, C., Lowe, S. W., Caplen, N. J., McCormick, F., & Luo, J. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817494116 · Cited by 126
“As an alternative strategy, inhibitors targeting RAS effectors, many of which are druggable kinases, have been a major focus in blocking oncogenic RAS signaling (3).”
BackgroundSelf-citationKoundinya, M., Sudhalter, J., Courjaud, A., Lionne, B., Touyer, G., Bonnet, L., Menguy, I., Schreiber, I., Perrault, C., Vougier, S., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.03.005 · Cited by 125
Mitochondria-targeted drugs stimulate mitophagy and abrogate colon cancer cell proliferation
Boyle, K. A., Van Wickle, J., Hill, R. B., Marchese, A., Kalyanaraman, B., & Dwinell, M. B. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001469 · Cited by 126
“Unfortunately, KRAS is a common genetic mutation, accounting for 50% of colorectal cancer oncogenic mutations (2, 3).”
BackgroundGlycogen Synthase Kinase 3β in Cancer Biology and Treatment
Domoto, T., Uehara, M., Bolidong, D., & Minamoto, T. (2020) · Cells · doi:10.3390/cells9061388 · Cited by 150
Afatinib restrains K-RAS–driven lung tumorigenesis
Moll, H. P., Pranz, K., Musteanu, M., Grabner, B., Hruschka, N., Mohrherr, J., Aigner, P., Stiedl, P., Brcic, L., Laszlo, V., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao2301 · Cited by 125
High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D
Sim, M. J. W., Lu, J., Spencer, M., Hopkins, F., Tran, E., Rosenberg, S. A., Long, E. O., & Sun, P. D. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1921964117 · Cited by 123
GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors
Kazi, A., Xiang, S., Yang, H., Delitto, D., Trevino, J., Jiang, R. H. Y., Ayaz, M., Lawrence, H. R., Kennedy, P., & Sebti, S. M. (2018) · Nature Communications · doi:10.1038/s41467-018-07644-6 · Cited by 122
Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors
Lv, X., Lu, X., Cao, J., Luo, Q., Ding, Y., Peng, F., Pataer, A., Lu, D., Han, D., Malmberg, E., et al. (2023) · Science · doi:10.1126/science.abn4180 · Cited by 123
Cong, V. T., Houng, J. L., Kavallaris, M., Chen, X., Tilley, R. D., & Gooding, J. J. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00707f · Cited by 135
Navigating the ERK1/2 MAPK Cascade
Martín-Vega, A., & Cobb, M. H. (2023) · Biomolecules · doi:10.3390/biom13101555 · Cited by 144
Petruzzella, E., Braude, J. P., Aldrich-Wright, J. R., Gandin, V., & Gibson, D. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201706739 · Cited by 121
KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing
Lim, T. K. H., Skoulidis, F., Kerr, K. M., Ahn, M., Kapp, J. R., Soares, F. A., & Yatabe, Y. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107293 · Cited by 152
Cregg, J., Edwards, A. V., Chang, S., Lee, B. J., Knox, J. E., Tomlinson, A. C. A., Marquez, A., Liu, Y., Freilich, R., Aay, N., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02314 · Cited by 151
Sanclemente, M., Francoz, S., Esteban-Burgos, L., Bousquet-Mur, E., Djurec, M., Lopez-Casas, P. P., Hidalgo, M., Guerra, C., Drosten, M., Musteanu, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.12.014 · Cited by 119
Quantitative Super-Resolution Microscopy of the Mammalian Glycocalyx
Möckl, L., Pedram, K., Roy, A. R., Krishnan, V., Gustavsson, A.-K., Dorigo, O., Bertozzi, C. R., & Moerner, W. E. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.04.035 · Cited by 119
“Ras is the prototypical oncogene, with mutations occurring in 9-30% of all diagnosed cancers, and is vital for a host of cellular processes that enable metastasis (Cox et al., 2014).”
BackgroundRAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Yang, X., & Wu, H. K. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01631-9 · Cited by 146
RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer
Yan, C., & Theodorescu, D. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014415 · Cited by 119
“synergistic activity between PI3K and RAF inhibitors has already been seen in human cell lines and mouse models (Cox et al., 2014).”
BackgroundInfluentialK-Ras(G12D)-selective inhibitory peptides generated by random peptide T7 phage display technology
Sakamoto, K., Kamada, Y., Sameshima, T., Yaguchi, M., Niida, A., Sasaki, S., Miwa, M., Ohkubo, S., Sakamoto, J.-I., Kamaura, M., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.01.147 · Cited by 118
Discovery of hidden allosteric sites as novel targets for allosteric drug design
Lu, S., Ji, M., Ni, D., & Zhang, J. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.10.001 · Cited by 123
Mechanisms of Resistance to KRASG12C Inhibitors
Dunnett-Kane, V., Nicola, P., Blackhall, F., & Lindsay, C. (2021) · Cancers · doi:10.3390/cancers13010151 · Cited by 117
“GEFs stimulate the dissociation of GDP and subsequent association of GTP, activating RAS proteins, while GAPs act to accelerate intrinsic GTP hydrolysis, converting RAS to its inactive state [2,3].”
BackgroundInfluentialWan, T., Chen, Y., Pan, Q., Xu, X., Kang, Y., Gao, X., Huang, F., Wu, C., & Ping, Y. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.03.015 · Cited by 118
Therapeutic resistance of pancreatic cancer: Roadmap to its reversal
Yu, S., Zhang, C., & Xie, K. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188461 · Cited by 127
Kolin, D. L., Costigan, D. C., Dong, F., Nucci, M. R., & Howitt, B. E. (2018) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001193 · Cited by 119
Protein phase separation and its role in tumorigenesis
Jiang, S., Fagman, J. B., Chen, C., Alberti, S., & Liu, B. (2020) · eLife · doi:10.7554/elife.60264 · Cited by 126
“adenocarcinoma, colorectal adenocarcinoma, and lung adenocarcinoma (Cox et al., 2014).”
BackgroundCurrent therapy of KRAS-mutant lung cancer
Ghimessy, A., Radeczky, P., Laszlo, V., Hegedus, B., Renyi-Vamos, F., Fillinger, J., Klepetko, W., Lang, C., Dome, B., & Megyesfalvi, Z. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09903-9 · Cited by 115
“However, despite the encouraging results in vitro, the use of Rce1 and ICMT inhibitors could impact the normal function of other proteins as well in vivo, raising the questions about normal tissue toxicity and possible side effects of these inhibitors [82].”
BackgroundTipifarnib as a Precision Therapy for HRAS -Mutant Head and Neck Squamous Cell Carcinomas
Gilardi, M., Wang, Z., Proietto, M., Chillà, A., Calleja-Valera, J. L., Goto, Y., Vanoni, M., Janes, M. R., Mikulski, Z., Gualberto, A., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0958 · Cited by 132
“RAS genes are the most common driver oncogenes in human cancer, being mutated in approximately one third of cancer cases, so considerable efforts have been made for decades to develop therapeutics forRAS-driven tumors (36).”
BackgroundPROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
Kelm, J. M., Pandey, D. S., Malin, E., Kansou, H., Arora, S., Kumar, R., & Gavande, N. S. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01707-5 · Cited by 110
Cho, K.-J., van der Hoeven, D., Zhou, Y., Maekawa, M., Ma, X., Chen, W., Fairn, G. D., & Hancock, J. F. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.00719-15 · Cited by 113
“EM analysis confirmed that fendiline significantly depleted K-Ras4A from the inner PM leaflet and also dis- A 0 min 60 min LactC2 K-Ras4B G12V B *** C on tro l Fe nd ili ne + P td S er + PI P 2 + PE + P C 0 100 200 300 400 Phospholipid N o. o f g ol d pa rti cl es (µ m -2 ) D. K-Ras4B G12V C on tro l Fe nd ili ne + P…”
BackgroundInfluentialJohnson, J. L., Ramadass, M., He, J. N., Brown, S. J., Zhang, J., Abgaryan, L., Biris, N., Gavathiotis, E., Rosen, H., & Catz, S. D. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.741884 · Cited by 140
“Although inhibitors of Rab-Rab effectors pairs have not been identified previously, two compounds that inhibit binding of Ras to the effector c-Raf-1 were identified, Kobe0065 and Kobe2602, that coincidentally contain nitrobenzene groups predicted to cause steric hindrance with the effector surface residues (56).”
BackgroundChandra, G., Singh, D. V., Mahato, G. K., & Patel, S. (2023) · Chemical Papers · doi:10.1007/s11696-023-02804-5 · Cited by 131
“The majority of RAS-driven cancers are caused by mutations in the KRAS isoform and mutations occurring most frequently in solid tumors such as lung adenocarcinoma, pancreatic ductal carcinoma, and colorectal carcinoma (Blair 2021; Chen et al. 2020; Cox et al. 2014).”
BackgroundShin, Y., Jeong, J. W., Wurz, R. P., Achanta, P., Arvedson, T., Bartberger, M. D., Campuzano, I. D. G., Fucini, R., Hansen, S. K., Ingersoll, J., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00258 · Cited by 113
Bear, A. S., Blanchard, T., Cesare, J., Ford, M. J., Richman, L. P., Xu, C., Baroja, M. L., McCuaig, S., Costeas, C., Gabunia, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24562-2 · Cited by 113
Therapeutic targeting of RAS: New hope for drugging the “undruggable”
Khan, I., Rhett, J. M., & O'Bryan, J. P. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.118570 · Cited by 110
“For example, KRAS is mutated in nearly 100% of pancreatic ductal adenocarcinoma (PDAC), with frequent mutational activation in lung (30%) and colorectal cancers (CRC)(45%) [9].”
BackgroundHu, H., Cheng, R., Wang, Y., Wang, X., Wu, J., Kong, Y., Zhan, S., Zhou, Z., Zhu, H., Yu, R., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci153470 · Cited by 118
“Despite 40 years of intensive efforts to develop targeted therapy for the KRAS oncoprotein, only AMG 510, a covalent inhibitor of the KRASG12C mutation, has just been approved by the FDA in May 2021; and targeting other KRAS mutations is still considered “mission impossible” (7, 8).”
BackgroundThe translational challenges of precision oncology
Pich, O., Bailey, C., Watkins, T. B. K., Zaccaria, S., Jamal‐Hanjani, M., & Swanton, C. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.002 · Cited by 123
Annual review of PROTAC degraders as anticancer agents in 2022
Wang, X., Qin, Z.-L., Li, N., Jia, M.-Q., Liu, Q.-G., Bai, Y., Song, J., Yuan, S., & Zhang, S. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116166 · Cited by 111
Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context
Kerk, S. A., Lin, L., Myers, A. L., Sutton, D. J., Andren, A., Sajjakulnukit, P., Zhang, L., Zhang, Y., Jiménez, J. A., Nelson, B. S., et al. (2022) · eLife · doi:10.7554/elife.73245 · Cited by 108
Schmick, M., Kraemer, A., & Bastiaens, P. I. H. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.02.004 · Cited by 126
Metadata
- Authors
- Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Vanderbilt University (US)
- Dana-Farber Cancer Institute (US)
- National Cancer Institute (US)
- Corresponding author
- Der, Channing J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-10-17
- Volume
- 13
- Issue
- 11
- Pages
- 828-851
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC4355017
- OpenAlex
- W2081990599
- Cited by
- 1,997
- References
- 231
- Citations by year
- 2026: 134 · 2025: 160 · 2024: 194 · 2023: 185 · 2022: 213 · 2021: 237 · 2020: 204 · 2019: 166 · 2018: 156 · 2017: 166 · 2016: 106 · 2015: 71 · 2014: 2
- FWCI
- 10.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (DP1OD006933, 5r01ca042978-30)
- U.S. Public Health Service (P50A095103-12)
- National Cancer Institute (P50CA127003, CA042978, R01CA175747, DP1CA174419, P50CA095103, CA175747, R01-CA042978, R21CA179193, RC2CA148375, CA179193, R01CA157490)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, RAS inhibitors, undruggable targets, synthetic lethality, RAS-mutant cancers, anticancer drug discovery, Ras signaling
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Signal Transduction, Oncogene Proteins, ras Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.